Emergent BioSolutions Inc

詳細情報 Emergent BioSolutions Inc 企業名

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

企業情報

企業コードEBS

会社名Emergent BioSolutions Inc

上場日Nov 15, 2006

最高経営責任者「CEO」Mr. Joseph C. (Joe) Papa

従業員数900

証券種類Ordinary Share

決算期末Nov 15

本社所在地300 Professional Dr

都市GAITHERSBURG

証券取引所NYSE Consolidated

国United States of America

郵便番号20879

電話番号12406313200

ウェブサイトhttps://emergentbiosolutions.com/

企業コードEBS

上場日Nov 15, 2006

最高経営責任者「CEO」Mr. Joseph C. (Joe) Papa

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

201.49K

-1.34%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

121.47K

-1.02%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

118.86K

+40.74%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

Mr. Ronald B. Richard

Independent Director

85.27K

+67.63%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

68.39K

+1061.66%

Mr. Marvin L. White

Independent Director

68.25K

+101.64%

Mr. Keith A. Katkin, CPA

Independent Director

66.14K

-10.60%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

342.50K

+21.24%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

201.49K

-1.34%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

121.47K

-1.02%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

118.86K

+40.74%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

103.49K

+49.80%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

91.98K

+211.99%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

MCM Product sales

156.60M

70.48%

Commercial Product sales

45.30M

20.39%

Contracts and grants

20.30M

9.14%

地域別USD

会社名

収益

比率

Non-U.S Government

143.40M

64.54%

U.S.Government

78.80M

35.46%

事業別

地域別

事業別USD

会社名

収益

比率

MCM Product sales

156.60M

70.48%

Commercial Product sales

45.30M

20.39%

Contracts and grants

20.30M

9.14%

株主

更新時刻: Thu, May 22

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

4.61%

American Century Investment Management, Inc.

4.23%

State Street Global Advisors (US)

3.15%

Dimensional Fund Advisors, L.P.

2.94%

Other

79.14%

株主統計

比率

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

4.61%

American Century Investment Management, Inc.

4.23%

State Street Global Advisors (US)

3.15%

Dimensional Fund Advisors, L.P.

2.94%

Other

79.14%

種類

株主統計

比率

Investment Advisor

26.89%

Investment Advisor/Hedge Fund

20.51%

Hedge Fund

14.34%

Research Firm

4.30%

Individual Investor

3.04%

Pension Fund

1.04%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.17%

Venture Capital

0.16%

Other

28.88%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

443

38.62M

71.16%

-7.77M

2025Q1

472

38.22M

70.45%

-8.61M

2024Q4

475

36.31M

66.90%

-8.91M

2024Q3

485

33.46M

61.86%

-11.26M

2024Q2

503

32.16M

60.76%

-21.31M

2024Q1

512

37.52M

71.59%

-17.68M

2023Q4

531

43.49M

83.79%

-11.00M

2023Q3

581

43.88M

84.66%

-15.71M

2023Q2

596

48.59M

93.79%

-8.52M

2023Q1

682

47.08M

93.36%

-12.05M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

3.21M

5.92%

+13.30K

+0.42%

Mar 31, 2025

Millennium Management LLC

2.50M

4.61%

+1.02M

+68.87%

Mar 31, 2025

American Century Investment Management, Inc.

2.30M

4.23%

+159.91K

+7.48%

Mar 31, 2025

State Street Global Advisors (US)

1.71M

3.15%

-253.01K

-12.88%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.60M

2.94%

+492.58K

+44.62%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.58M

2.92%

-61.06K

-3.71%

Mar 31, 2025

Marshall Wace LLP

1.16M

2.13%

-170.78K

-12.85%

Mar 31, 2025

Palisade Capital Management, LLC

1.14M

2.1%

+202.86K

+21.61%

Mar 31, 2025

Oak Hill Advisors, L.P.

1.11M

2.05%

--

Mar 31, 2025

Qube Research & Technologies Ltd

1.09M

2%

+271.55K

+33.29%

Mar 31, 2025

詳細を見る

5.960USD

Emergent BioSolutions Inc

5.960

概要

企業名

金融